Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint In ACHIEVE-5, orforglipron lowered A1C by an additional 2.1% when taken with insulin glargine, meeting the primary endpoint 1,2,3 "Orforglipron has now demonstrated superiority over two active comparators in clinical trials for type 2 diabetes," said In both trials, the overall safety and tolerability profile of orforglipron, as well as treatment discontinuation rates, were consistent with previous studies
Monitoring glucose levels in urine using FTIR spectroscopy combined with univariate and multivariate statistical methods
He may also ask about your medical history and medications youre taking to minimize your risk of an adverse reaction
That research is important, but it is not proof that GLP-1s should be used casually or as microdoses for dementia prevention
US$ 25.57
US$ 24.48
US$ 20.57
